What's in David Garcia Cinca's pipeline?

David Garcia Cinca has 5 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with David Garcia Cinca's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/david-garcia-cinca.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

David Garcia Cinca — Portfolio Competitive Intelligence Brief

David Garcia Cinca pipeline: 0 marketed, 0 filed, 2 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Bicarbonate endovenous hydratation	Bicarbonate endovenous hydratation	phase 3	Electrolyte/alkalizing agent		Nephrology
Saline endovenous hydratation	Saline endovenous hydratation	phase 3			Fluid and Electrolyte Management

Therapeutic area mix

Fluid and Electrolyte Management · 1
Nephrology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for David Garcia Cinca:

Cite this brief

Drug Landscape (2026). David Garcia Cinca — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/david-garcia-cinca. Accessed 2026-05-16.